4D Molecular Therapeutics (FDMT) Net Cash Flow Growth (1y) (2021 - 2026)
Powered by 
Analysis
4D Molecular Therapeutics (FDMT) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 172.72% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 53.21% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 47.11% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.60% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -100.75% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 149.49% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -104.22% |
| 10 | 4D Molecular Therapeutics | 1.05 Bn | 692.04 Mn | - | 96.25% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 96.25% |
| Mar 31, 2026 | 177.46% |
| Dec 31, 2025 | 130.59% |
| Sep 30, 2025 | -1,779.37% |
| Jun 30, 2025 | 34.86% |
| Mar 31, 2025 | -159.69% |
| Dec 31, 2024 | -43.78% |
| Sep 30, 2024 | -103.87% |
| Jun 30, 2024 | -154.86% |
| Mar 31, 2024 | 1.02% |
| Dec 31, 2023 | 52.51% |
| Sep 30, 2023 | 859.10% |
| Jun 30, 2023 | 320.49% |
| Mar 31, 2023 | 134.04% |
| Dec 31, 2022 | -190.22% |
| Sep 30, 2022 | 96.60% |
| Jun 30, 2022 | 332.69% |
| Mar 31, 2022 | -356.86% |
| Dec 31, 2021 | -67.01% |
| Sep 30, 2021 | -1,160.14% |